Patent application enters PCT phase, SpectraCure ensures development and work
SpectraCure’s work and development proceeds with several parallel projects. A patent application which covers a new technology that improves upon the Company’s IDOSE technology is now progressing to the so-called PCT phase, which is a way of coordinating patent applications in all the countries of the world. This is a result of the positive outcome […]
New study underway in the US and approval from the Food and Drug Administration (FDA)
The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA, was held as scheduled on Friday. As previously announced, it was a formal meeting for the start-up and review of routines and equipment. – I am very excited about the study and look forward to start patient recruitment, says James A. Eastham, Chief of the Urology Service at Memorial Sloan […]
The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA takes place tomorrow, March 13 2020
Refers to the latest travel information regarding the United States. The scheduled meeting, "Site Initiation Visit", between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA, will be conducted tomorrow Friday. It is a formal meeting for the start-up and review of procedures and equipment. After the meeting is completed, the study is underway and recruitment of […]
Agreement reached between SpectraCure and one more hospital – Memorial Sloan Kettering Cancer Center i n New York
SpectraCure AB (publ) and Memorial Sloan Kettering Cancer Center in New York, USA, have today signed an agreement, which means that the hospital will be the fourth hospital in SpectraCure's clinical program. A formal meeting ("Site Initiation Visit") for the start-up and review of routines and equipment will be arranged between the company and the […]
Reinforcements in SpectraCure’s organization
Today we are welcoming Johan Glindre to SpectraCure. Johan Glindre will be working as a Clinical Project Leader and has a solid background in clinical studies, project management and quality work. Johan holds a Master of Molecular Biology from Lund University, and has among other things, been working for Pharmacia and OctaPharma with quality work […]
A welcome addition to support our ongoing product development. SpectraCure receives research contribution from the EU.
SpectraCure (http://www.SpectraCure.com)has been awarded with funds from the EU which strengthens the research within the company’s technology, to treat prostate cancer with SpectraCure’s IDOSE dose platform and focal PDT treatment (PDT). The funding enables the employment of a young researcher for four years. The funding is part of an Innovative Training Network where SpectraCure participates […]
The FDA’s initiative can provide faster market access for SpectraCure
During SpectraCure's ongoing clinical trial, the American FDA (Food and Drug Administration) has created an opening for faster product launch by changing the requirements for endpoints in clinical trials in cancer treatment. The changed requirements provide new opportunities that in the long term may entail faster market access. The FDA's initiative to admit shorter […]
SpectraCure at Stora Aktiedagen in Gothenburg
A new opportunity to listen to Masoud Khayyami, CEO of SpectraCure, will be at Stora Aktiedagen in Gothenburg November 4th. The SpectraCure Company presentation, including the status of current clinical study, will be held at 1.30 p m. The event will be streamed at www.aktiespararna.se/tv/live. Where: Hall G3, Svenska Mässan, Mässans Gata 24, Gothenburg For further information, contact: SpectraCure […]
SpectraCure to the Premier Segment of First North Growth Market
SpectraCure AB (publ) announces today that Nasdaq has approved the Company's application to move its stock trading to First North Premier Growth Market. The transfer is an important step towards a future listing on Nasdaq Stockholm’s main market. The trade in SpectraCure’s shares on First North Premier Growth Market will be initiated on Thursday, October […]
Correction: Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial
Correction concerning inaccurate reference under the EU Market Abuse Regulation (MAR). The pressrelease without reference is found below. Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial The collaboration between SpectraCure and the German company MedCom GmbH has reached a stage where the technology will be used […]
